Premium
Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients
Author(s) -
Jensen Line R.,
Garzon Benjamin,
Heldahl Mariann G.,
Bathen Tone F.,
Lundgren Steinar,
Gribbestad Ingrid S.
Publication year - 2011
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.22726
Subject(s) - medicine , breast cancer , effective diffusion coefficient , intraclass correlation , diffusion mri , dynamic contrast enhanced mri , chemotherapy , magnetic resonance imaging , nuclear medicine , cancer , breast mri , radiology , mammography , clinical psychology , psychometrics
Purpose: To use dynamic contrast‐enhanced (DCE) and diffusion‐weighted (DW) MRI at 3 Tesla (T) for early evaluation of treatment effects in breast cancer patients undergoing neoadjuvant chemotherapy (NAC), and assess the reliability of DW‐MRI. Materials and Methods: DW‐ and DCE‐MRI acquisitions of 15 breast cancer patients were performed before and after one cycle of NAC. MRI tumor diameter and volume, apparent diffusion coefficient (ADC) and kinetic parameters (K trans , v e ) were derived. The reliability of ADC before NAC was assessed. Changes in MRI parameters after NAC were analyzed, and logistic regression analysis was used to find the best predictors for pathologic response. Results: The reliability for ADC values was high, with intraclass correlation coefficient of 0.84 ( P = 0.001). After one cycle of NAC, MRI tumor diameter (8%, P = 0.005) and tumor volume (30%, P = 0.008) was reduced for all patients, while ADC mean values increased (0.12 mm 2 /s, P = 0.008). The best predictor for treatment response was a change in MRI tumor diameter with mean error rate of 0.167 (13% for responders, 5% for nonresponders, P = 0.291). Conclusion: Changes in MRI derived tumor diameter and ADC after only one cycle of NAC could provide a valuable tool for early evaluation of treatment effects in breast cancer patients. J. Magn. Reson. Imaging 2011;. © 2011 Wiley Periodicals, Inc.